Study design

The choice of study design in paediatric clinical research is shaped by the nature of the research question, the available evidence base, the characteristics of the target population and the stage of the development pathway as well as by ethical constraints, practical recruitment limitations and the need to maximize the information obtained from each participant.

For drug development, the choice of study design will depend on where the product is in the development pathway. Open-label single-arm designs are typically used in Phase I and II to evaluate safety, tolerability and dosing. Randomized controlled trials are the gold standard for confirming efficacy and safety, comparing a novel product against a control arm receiving either a placebo, when no existing treatment is available, or standard of care.

Open-label single-arm trials

Open-label single-arm trials, in which all participants receive the investigational treatment and there is no blinding or control group, are commonly used in early-phase paediatric studies and in settings in which a placebo control would be unethical or impractical. They are particularly common in rare disease research. Although they can provide important preliminary evidence of safety, pharmacokinetic and activity, the absence of a control group limits causal inference about efficacy. Phase I trials are generally open-label single-arm trials and sometimes Phase II for paediatric cancer or rare diseases.

Randomized controlled trials

Randomized controlled trials remain the gold standard for evaluating the efficacy of interventions. Phase III generally uses a randomized controlled trial model to confirm the efficacy of a new product against a comparator, either a placebo or standard of care. In paediatric randomized controlled trials, randomization ensures that known and unknown confounders are distributed equally between treatment arms, enabling valid causal inference. However, the ethical and practical constraints of paediatric research, especially the use of placebo controls when effective treatments exist, small population sizes and the challenges of blinding age-appropriate formulations, mean that the standard randomized controlled trial design frequently needs to be adapted.

Practical approaches

The open-label single-arm and randomized controlled trial designs described above form the backbone of confirmatory paediatric drug development in Phases I through III. However, broader methodological approaches or designs are available to researchers when the scientific question, population size or practical context calls for a different design (Table 2). Some of these designs improve efficiency in exploratory or confirmatory trials in which small populations, multiple treatment arms or rapid evidence accumulation make a standard parallel-group randomized controlled trial impractical. Others are better suited to community-based or public health questions or to settings in which the goal is to evaluate treatments under real-world conditions rather than tightly controlled experimental ones. The approaches and methods described below are each suited to a specific context or research question across the research continuum.

Table 2. Practical study design approaches and methods used in paediatric clinical research and analysis.

DesignKey mechanismPaediatric applicationKey consideration
Adaptive designsPrespecified modifications to sample size, randomization ratios or arms based on accumulating dataOncology, infectious disease; includes multi-arm multi-stage designsImproves efficiency, reduces participant burden, enables early stopping for efficacy or futility – without compromising statistical validity
Platform trialsEvaluates multiple interventions against a shared control within a single, perpetual master protocol; arms can be added or dropped over timeIncreasingly used in paediatric oncology and infectious disease research to test successive therapies without launching new trials each timeRequires robust infrastructure and governance to manage evolving arms; shared control group improves efficiency but requires careful handling of temporal drift
Cluster randomized trialsRandomizes groups (schools, clinics, communities) rather than individualsCommunity-based research, vaccine trials, public health interventionsUsed when individual randomization is impractical or contamination between arms is a concern; requires statistical adjustment for intracluster correlation
Basket trialsSingle intervention tested across multiple diseases or subgroups defined by a shared featurePaediatric oncology, rare disease, diseases with heterogeneous subpopulations, such as HIV treatment-naive versus treatment-experienced children (see Box 11)Grouping into baskets can be by molecular target, diagnosis or other therapeutic characteristics (age and weight bands, coinfection status, treatment experience)
Crossover trialsEach participant receives multiple treatments in sequence, serving as their own controlChronic or stable paediatric conditions; for testing the bioequivalence of new formulationsOnly appropriate when carry-over effects can be excluded or managed via washout and the condition is unlikely to change between periods; reduces required sample size
Factorial designsSimultaneously tests two or more interventions (and their combinations) within a single trialEfficient for evaluating independent interventions in the same paediatric population (such as testing a drug and a delivery-device intervention together)Can efficiently answer multiple questions in one trial. If interaction effects are observed, the groups have to be analysed separately
Bayesian borrowingStatistical method that incorporates relevant prior information – data from adults or historical paediatric studies – into the analysis of paediatric trial dataCan support paediatric dose selection, estimation of treatment effects and evaluation of safety and efficacy when paediatric sample sizes are smallRequires justification of the relevance and comparability of external data to the paediatric population, including differences in disease, pharmacology, age and clinical outcomes
Box 11. ODYSSEY trial — a basket paediatric trial design for children living with HIV

The ODYSSEY trial was a global, open-label, randomized Phase II/III non-inferiority trial evaluating dolutegravir-based antiretroviral therapy compared with standard of care among children and adolescents living with HIV. Its basket design enabled the simultaneous evaluation of two cohorts: children starting first-line treatment (ODYSSEY A) and those switching to second-line treatment (ODYSSEY B), using a shared trial infrastructure and treatment comparison. Nested pharmacokinetic substudies also evaluated dosing across paediatric weight bands, including younger and smaller children. This design addressed multiple research questions efficiently within one trial while enabling outcomes to be assessed across the distinct treatment cohorts.

Source: Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM et al. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. BMC Infect Dis. 2021;21(1):5 (https://doi.org/10.1186/s12879-020-05672-6).

Key resources